Literature DB >> 22217990

Evaluation of in vitro cytotoxicity of oxaliplatin and 5-fluorouracil in human colon cancer cell lines: combination versus sequential exposure.

A Failli1, R Consolini, A Legitimo, G Orsini, A Romanini, R Spisni, M Castagna, P Miccoli.   

Abstract

Adjuvant therapy has evolved to become the standard care of colon cancer, but the tumor capability of activating effective mechanisms of defence against both chemical and physical cytotoxic agents represents a serious obstacle to the successful therapy. Furthermore, the possibility to have an assay useful to measure the drug sensitivity of tumor cells could be of a great importance. As primary human colon cancer cultures from fresh tumor are technically difficult to obtain, experiments with human cancer cell lines remain essential to explore new adjuvant chemotherapy drugs, to investigate the individual responsiveness to the known agents, and particularly to clarify how these chemotherapeutic agents could be used in maximizing outcomes. In the present study we evaluate the cytotoxic effects of 5-fluorouracil (5-FU) and oxaliplatin (OHP) and of their pharmacological interaction in three human colon cancer cell lines (WiDr, HT-29 and SW620), by using an ATP luminescence assay (ATPlite; Perkin Elmer), displaying high sensitivity, linearity and reproducibility. Cell cycle, apoptosis and CD44 expression were investigated with flow cytometry. Our results show that the drug combinations inhibited the cell growth more than each drug alone in all colorectal cancer cell lines. Interestingly, the sequential exposure of OHP and 5-FU resulted in the most cytotoxic effect in all colon cancer cell lines, when compared to the simultaneous one. Our results focus on the powerful cytotoxic effect of 5-FU-OHP combination, when used in sequential exposure, suggesting interesting implications for a rational use of 5-FU, OHP combination in colon-rectal cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22217990

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  3 in total

1.  FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures.

Authors:  Taylor J Allen-Coyle; Jin Niu; Eva Welsch; Neil T Conlon; Weylon Garner; Martin Clynes; Finbarr O'Sullivan; Robert M Straubinger; Donald E Mager; Sandra Roche
Journal:  AAPS J       Date:  2022-10-13       Impact factor: 3.603

2.  Post-Marketing Surveillance of a generic Oxaliplatin (Alvoxal) in Iranian Patients with Cancer.

Authors:  Farhad Shahi; Mojtaba Gorji; Mehrdad Payandeh; Hamid Rezvani; Mohammad Vaezi; Sharareh Seifi; Alireza Baari; Reza Khalili-Dizaji; Seyed Mehdi Hashemi; Saeid Salimi; Hosein Kamranzadeh; Babak Shazad; Sina Salari; Davoud Oulad Dameshghi; Mehdi Sarkheil; Mehrzad Mirzania; Nassim Anjidani
Journal:  Curr Ther Res Clin Exp       Date:  2021-11-29

3.  Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells.

Authors:  Meng-Fei Lau; Shalini Vellasamy; Kek-Heng Chua; Vikineswary Sabaratnam; Umah Rani Kuppusamy
Journal:  EXCLI J       Date:  2018-02-06       Impact factor: 4.068

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.